長春瑞濱聯(lián)合順鉑治療阿霉素耐藥的晚期乳腺癌的效果研究

楊飛

【摘要】 目的：分析長春瑞濱聯(lián)合順鉑治療阿霉素耐藥的晚期乳腺癌的臨床效果，為阿霉素耐藥的晚期乳腺癌的臨床治療提供科學(xué)參考依據(jù)。方法：選取2012年1月-2013年12月本院收治的阿霉素耐藥的晚期乳腺癌患者100例作為研究對象，將其隨機分為觀察組與對照組，各50例。觀察組采用長春瑞濱聯(lián)合順鉑治療，對照組采用吉西他濱聯(lián)合順鉑治療，比較兩組的近期療效、遠期療效、安全性與不良反應(yīng)。結(jié)果：兩組患者的近期療效比較，差異無統(tǒng)計學(xué)意義（P>0.05）；觀察組無進展生存期和總生存時間均明顯優(yōu)于對照組（P<0.05）；觀察組不良反應(yīng)發(fā)生率均顯著低于對照組（P<0.05）。結(jié)論：長春瑞濱聯(lián)合順鉑與吉他西濱聯(lián)合順鉑在治療阿霉素耐藥的晚期乳腺癌的近期療效相似，但長春瑞濱聯(lián)合順鉑的遠期療效更加顯著且安全性更高，值得在臨床中推廣使用。

【關(guān)鍵詞】 長春瑞濱； 順鉑； 阿霉素耐藥； 晚期乳腺癌

Study on the Effect of Vinorelbine Combined with Cisplatin in the Treatment of Adriamycin Resistant Advanced Breast Cancer/YANG Fei.//Medical Innovation of China，2017，14（27）：038-041

【Abstract】 Objective：To analyze the clinical effect of Vinorelbine combined with Cisplatin in the treatment of adriamycin resistant advanced breast cancer，so as to provide a scientific basis for the clinical treatment of adriamycin resistant advanced breast cancer.Method：100 cases of adriamycin resistant advanced breast cancer in our hospital from January 2012 to December 2013 were selected as the research objects，they were randomly divided into the observation group and the control group，50 cases in each group.The observation group was treated with Vinorelbine combined with Cisplatin，and the control group was treated with Gemcitabine combined with Cisplatin.The short-term efficacy，long-term efficacy，safety and adverse reactions were compared of two groups.Result：The short-term efficacy were compared of two groups，the difference was not statistically significant（P>0.05），the progression free survival and overall survival of the observation group were significantly better than those of the control group（P<0.05），the adverse reactions of the observation group were significantly lower than those of the control group（P<0.05）.Conclusion：Vinorelbine combined with Cisplatin and Gemcitabine combined with Cisplatin has similar therapeutic effect in the treatment of adriamycin resistant advanced breast cancer，but the long-term efficacy of Vinorelbine combined with Cisplatin is more significant and higher safety，and is worthy of promotion in clinical use.

【Key words】 Vinorelbine； Cisplatin； Adriamycin resistance； Advanced breast cancer

First-authors address：The Affiliated Huaian Hospital of Xuzhou Medical University，Huaian 223002，China

doi：10.3969/j.issn.1674-4985.2017.27.011

乳腺癌是一種常見的女性惡性腫瘤，具有較高的生物惡性，隨著近些年女性工作壓力和生活環(huán)境的變化，該病的發(fā)生率呈逐年增長的趨勢，對女性的健康造成了嚴重的威脅[1]。乳腺癌臨床常用的治療方法為手術(shù)治療、化療、放療、理療等方案，但由于該病早期無明顯癥狀，一旦患者出現(xiàn)明顯體征，多發(fā)展至中晚期，錯過了最佳手術(shù)時期[2-3]。化療是目前晚期乳腺癌比較有效的治療措施，但患者易對化療藥物產(chǎn)生耐藥性，產(chǎn)生耐藥性之后的治療藥物選擇空間較小，因此復(fù)發(fā)率和轉(zhuǎn)移率較高[4]。因此，筆者主要針對長春瑞濱聯(lián)合順鉑治療阿霉素耐藥的晚期乳腺癌的臨床療效展開分析，現(xiàn)報道如下。endprint

1 資料與方法

1.1 一般資料 選取2012年1月-2013年12月本院收治的阿霉素耐藥的晚期乳腺癌患者100例作為研究對象，納入標準：（1）經(jīng)病理組織檢查確診為乳腺癌且臨床分期為晚期。（2……